Cystic Fibrosis Clinical Trial
— SNACK_CFOfficial title:
The Effect of a Pre-meal Snack and/or Exercise on Post-prandial Glycemic Excursions in Adults With Cystic Fibrosis
Verified date | April 2023 |
Source | Institut de Recherches Cliniques de Montreal |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators aim to test the feasibility and effectiveness of a pre-meal snack to reduce the postprandial glycemia (PPG) excursion after a breakfast consumption in adult patients with cystic fibrosis (CF). The investigators also want to investigate the impact of a postprandial exercise to reduce the PPG excursion. An improvement in PPG excursions can improve the condition of CF patients primarily by delaying the onset of cystic fibrosis related diabetes (CFRD) and / or by reducing the risk of lung function loss.
Status | Completed |
Enrollment | 14 |
Est. completion date | December 31, 2022 |
Est. primary completion date | May 26, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of cystic fibrosis, - Be over 18 years old. Exclusion Criteria: - Pharmacological treatment for cystic fibrosis related diabetes. - Signs of secondary infection: the test will be practiced at least 1 month after the end of infection treatment - People with severe gastrointestinal illness (Crohn's disease, celiac disease and a recent history (<1 year) of bowel obstruction). - Allergy to one of the ingredients of the menu (example: celiac disease) - According to the judgment of the investigator, medications or conditions that could interfere with glucose metabolism (eg: oral steroids) - Pregnancy in progress - Corrector or potentiator prescribed whose dose is not stable the last 2 months. |
Country | Name | City | State |
---|---|---|---|
Canada | Institut de Recherches Cliniques de Montréal (IRCM) | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Institut de Recherches Cliniques de Montreal |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total area under the curve for plasma glucose | Overall study period (4 hours) | ||
Secondary | Area under the curve for plasma glucose | From start of study to breakfast time (1 hour) | ||
Secondary | Area under the curve for plasma glucose | From time of breakfast to the end of the study (3 hours) | ||
Secondary | Total area under the curve for insulin | Overall study period (4 hours) | ||
Secondary | Area under the curve for insulin | From start of study to breakfast time (1 hour) | ||
Secondary | Area under the curve for insulin | From breakfast time to the end of the study (3 hours) | ||
Secondary | Mean plasma glucose | Overall study period (4 hours) | ||
Secondary | Mean insulin | Overall study period (4 hours) | ||
Secondary | Percentage of time with plasma glucose concentration above 8.0 mmol/L | Overall study period (4 hours) | ||
Secondary | Percentage of time with plasma glucose concentration above 10.0 mmol/L | Overall study period (4 hours) | ||
Secondary | Percentage of time with plasma glucose concentration above 11.0 mmol/L | Overall study period (4 hours) | ||
Secondary | Percentage of time with plasma glucose concentration below 4.0 mmol/L | Overall study period (4 hours) | ||
Secondary | Post-breakfast peak plasma glucose | 1 hour after breakfast |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |